Document is current
Any future updates will be listed below
-
Authors
Appiah, Sandra A.
Foxx, Christine L.
Langgartner, Dominik
Palmer, Annette
Zambrano, Cristian A.
Braumüller, Sonja
Schaefer, Evan J.
Wachter, Ulrich
Elam, Brooke L.
Radermacher, Peter
Stamper, Christopher E.
Heinze, Jared D.
Salazar, Stephanie N.
Luthens, Amalia K.
Arnold, Andrea L.
Reber, Stefan O.
Huber-Lang, Markus
Lowry, Christopher A.
Halbgebauer, Rebecca
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (251293561, 251293561)
National Institute of Mental Health (1R21MH116263)
National Center for Complementary and Integrative Health (R01AT010005)
Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Accelerator Program (CTGG1-2020-3064)
Universität Ulm
- License Information
-
More Information
Article History
Received: 6 November 2020
Accepted: 5 March 2021
First Online: 23 March 2021
Competing interests
: CL serves on the Scientific Advisory Board of Immodulon Therapeutics, Ltd., is cofounder and Chief Scientific Officer of Mycobacteria Therapeutics Corporation, and serves as an unpaid scientific consultant with Aurum Switzerland AG. CL is also a member of the Faculty of the Integrative Psychiatry Institute. The other authors declare no competing interests.
